Two Nottinghamshire businesses have been selected as winners at the prestigious Medilink East Midlands Business awards 2017; NuVision Biotherapies Ltd, based at MediCity, and Promethean Particles, based at Genesis Park.
NuVision Biotherapies was established in 2015 as a spin out company of The University of Nottingham. It is developing ground-breaking treatments for eye disease and trauma and its regenerative therapy Omnigen® has already been supplied to over 60 clinical and veterinary centres. In less than two years NuVision has established itself as a highly successful biotech company, and this has been recognised with the company winning Medilink Start-up award.
Dr Andrew Hopkinson, Chief Executive Officer, commented;
“Since we established in 2015, NuVision and Omnigen® have gone strength to strength, and it’s great that we can now add the Medilink East Midlands Start-up award to our list of achievements.”
The Start-up award was sponsored by BioCity Group.
Glenn Crocker, Chief Executive Officer, commented;
“The Medilink East Midlands start-up award is close to BioCity’s heart as it recognises companies in the early stages who are making great strides in their field. NuVision Biotherapies couldn’t be more deserving of this award and we look forward to seeing further progression and development.”
The Outstanding achievement award went to Promethean Particles, who two years ago opened the world’s largest continuous multi-nanomaterial manufacturing plant. This was very successful and the company now possess full scale manufacturing capabilities, and commercialise their solutions worldwide.
Anais Venet, Global Business Development Manager, commented;
“We are delighted to have won the Medilink East Midlands Outstanding Achievement award, and I’d like to thank the entire company for their hard work. Having opened a new manufacturing plant in May 2016 many people had to learn new skills to ensure its success, so it really has been a team effort.”
The Outstanding Achievement award was sponsored by Morningside Pharmaceuticals.
Dr Nik Kotecha, Chief Executive Officer commented;
“We are thrilled that Promethean Particles have been awarded in what was a really competitive category. Morningside Pharmaceuticals are proud to sponsor an award that recognises achievements of such significance in the Life Sciences sector.”
The Medilink East Midlands awards were held as part of the annual Innovation Day on Thursday 15thJune at The DoubleTree by Hilton, Nottingham and companies were presented with awards in five categories: Start-up, Export Achievement, Collaboration with the NHS, Innovation and Outstanding Achievement.
Innovation Day, now in its 13th year, is the premier East Midlands event for the Life Sciences industry, and 2017 was another huge success, with over 200 delegates in attendance. Speakers included Vivienne Parry OBE who hosted the day, Sir John Peace, Chairman of The Midlands Engine, John Jeans, MedTech Champion for Office for Life Sciences and Richard Bradley, Pharmacy Director for Boots UK and Republic of Ireland.
NuVision Biotherapies and Promethean Particles will both be automatically shortlisted for the Medilink UK National Awards, which will take place in April 2018.
Dr Darren Clark, Chief Executive of Medilink East Midlands commented:
“Medilink East Midlands is committed to supporting new and existing companies throughout their growth and development. Both of these companies have had an outstanding year and couldn’t be more deserving of their awards.”
For further information please visit www.medilinkmidlands.com/events/innovation-day-2017
For photography requests or to contact the winners please email info@medilinkem.com